^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD8 positive

i
Other names: CD8, CD8A, cluster of differentiation 8, CD8a Molecule, T-Cell Surface Glycoprotein CD8 Alpha Chain, T-Lymphocyte Differentiation Antigen T8/Leu-2, CD8 Antigen, Alpha Polypeptide (P32), Leu2 T-Lymphocyte Antigen, OKT8 T-Cell Antigen, T-Cell Antigen Leu2, T Cell Co-Receptor, T8 T-Cell Antigen, CD8a Antigen
Entrez ID:
Related biomarkers:
Related tests:
8d
Prediction of Treatment Response Based on Nutritional Status and Tumor Immunity in Oropharyngeal Cancer Patients Treated With Chemoradiotherapy. (PubMed, Cancer Diagn Progn)
A combined risk score incorporating clinical, nutritional, and immune factors can improve the prediction of treatment outcomes for OPC patients. This risk stratification may enable personalized treatment plans and improve ΟS rates.
Journal
|
CD8 (cluster of differentiation 8)
|
CD8 expression • CD8 positive
9d
Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity. (PubMed, Cancer Immunol Immunother)
We previously developed a telomerase-specific oncolytic adenovirus (OBP-301) and a p53-armed OBP-301 (OBP-702), demonstrating that these viruses strongly activate systemic antitumor immunity. Intratumoral injection of OBP-702 into PAN02 subcutaneous tumors significantly increased the presence of mature DCs and CD8-positive T cells in draining lymph nodes, leading to long-lasting antitumor effects through the durable activation of systemic antitumor immunity. In conclusion, tumor-derived exosomes play a significant role in DC maturation following OBP-702 treatment and are critical for the systemic activation of antitumor immunity, leading to the abscopal effect.
Journal • Oncolytic virus • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
|
CD8 positive
|
Telomelysin (suratadenoturev) • pfifteloxin (OBP-702)
16d
Prognostic Significance of T-Cells and Macrophages in the Tumour Microenvironment of Nodal DLBCL. (PubMed, Indian J Hematol Blood Transfus)
Multivariate Cox regression survival analysis revealed that cases with 'good' R-IPI prognostic score and 'high CD68 positive macrophages in tumor microenvironment' had a significantly longer overall survival. Increased number of cytotoxic T-cells was significantly associated with complete response to treatment and higher number of macrophages correlated significantly with better overall survival signifying their antitumor effects.
Journal
|
CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3)
|
CD8 positive • CD68 positive
19d
First reported case of thymoma-associated multiorgan autoimmunity induced by COVID-19. (PubMed, J Dermatol)
A 64-year-old female patient with a history of myasthenia gravis and thymoma treated with prednisolone (10 mg/day) and cyclosporine (150 mg/day) experienced erythema on her trunk after coronavirus disease 2019 (COVID-19) onset...During the disease course, candida fungemia and cytomegalovirus infection developed, resulting in the patient's death. The TAMA was considered to have been caused by the release of inflammatory cytokines, autoreactive T cell activation, and regulatory T cell dysfunction induced by COVID-19.
Journal
|
CD8 (cluster of differentiation 8)
|
CD8 positive
|
cyclosporine
29d
Bioceramics Enhance the Anti-Tumor Activity of Immune Cells in Adoptive Immunotherapy. (PubMed, Int J Mol Sci)
The results of the in vivo evaluation indicated that the CPSB ceramics significantly inhibited tumor growth when CD8-positive T cells were cultured on individual ceramics and subsequently injected into tumor-bearing mice. The present CPSB ceramics are expected to be a valuable biomaterial for immunotherapy.
Journal • Immune cell
|
CD8 (cluster of differentiation 8)
|
CD8 positive
1m
CD8 positive T-cells decrease neurogenesis and induce anxiety-like behaviour following hepatitis B vaccination. (PubMed, Brain Commun)
Our findings highlight the role of glial cell derived CXCL16 in mediating the recruitment of CXCR6+CD8+ T cell subsets into the brain. This mechanism represents a potential avenue for modulating hippocampal neurogenesis and emotion-related behaviours after hepatitis B vaccination.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • CXCL16 (C-X-C Motif Chemokine Ligand 16)
|
CD8 positive
1m
Clinical Significance of Granzyme B Gene Expression in Pathological Stage II/III Gastric Cancer After Curative Gastrectomy. (PubMed, Anticancer Res)
In patients with locally advanced GC after curative resection, GZMB expression in GC tissue may be a useful prognostic marker.
Journal
|
CD8 (cluster of differentiation 8) • GZMB (Granzyme B)
|
CD8 positive
1m
CD8-Positive T-Cells Are Key Immune Cells for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy in Triple-negative Breast Cancer. (PubMed, Anticancer Res)
Assessing infiltration by CD8-positive TILs in the primary tumor is a useful biomarker to predict pCR and improved outcome in patients with node-positive TNBC.
Journal • Immune cell
|
CD8 (cluster of differentiation 8) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • ITGAX (Integrin Subunit Alpha X)
|
CD8 positive
2ms
An Unconventional Case Study of Neoadjuvant Oncolytic Virotherapy for Recurrent Breast Cancer. (PubMed, Vaccines (Basel))
Here, we describe the unique case of a 50-year-old self-experimenting female virologist with locally recurrent muscle-invasive breast cancer who was able to proceed to simple, non-invasive tumour resection after receiving multiple intratumoural injections of research-grade virus preparations, which first included an Edmonston-Zagreb measles vaccine strain (MeV) and then a vesicular stomatitis virus Indiana strain (VSV), both prepared in her own laboratory. The patient completed one-year trastuzumab adjuvant therapy and remains well and recurrence-free 45 months post-surgery. Although an isolated case, it encourages consideration of oncolytic virotherapy as a neoadjuvant treatment modality.
Journal • Oncolytic virus • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • CD20 positive • PD-L1 negative • CD8 positive
|
Herceptin (trastuzumab)
2ms
CD8 + T-cells restrict the development of peritoneal metastasis and support the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC). (PubMed, Sci Rep)
The presence of CD8 + T-cells within PM lesions is associated with prolonged survival of patients with PM. Data from PM mouse model and in-vitro assay show that heated chemotherapies induce immunogenic changes on cancer cells leading to induction of CD8 + T-cells mediated immunity, which seems to control growth of PM lesions in mice after HIPEC.
Journal
|
CD8 (cluster of differentiation 8) • CCNA1 (Cyclin A1)
|
CD8 positive
2ms
Journal
|
CD8 (cluster of differentiation 8)
|
CD8 expression • CD8 positive
2ms
PD-1+ and TIM-3+ T cells widely express common γ-chain cytokine receptors in multiple myeloma patients, and IL-2, IL-7, IL-15 stimulation up-regulates PD-1 and TIM-3 on T cells. (PubMed, Oncol Res)
Differences in common γ-chain cytokine receptor expression between PD-1+ and TIM-3+ T cells may reflect functional dissimilarity of these cell subsets. Checkpoint blockade appears to alleviate lymphopenia-induced proliferation of PD-1+ T cells but may raise the possibility of immune-mediated adverse events.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL7R (Interleukin 7 Receptor) • IL15 (Interleukin 15) • IL7 (Interleukin 7)
|
CD8 expression • CD8 positive • HAVCR2 expression • IL2RA expression
2ms
PVSRIPO for Patients With Unresectable Melanoma (clinicaltrials.gov)
P1, N=12, Terminated, Istari Oncology, Inc. | Completed --> Terminated; Study closed to enrollment due to business decision prior to enrolling Cohort 4
Trial termination
|
BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • PVR (PVR Cell Adhesion Molecule)
|
BRAF mutation • BRAF wild-type • CD8 positive
|
lerapolturev (PVS-RIPO)
2ms
PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients. (PubMed, Cells)
In U2OS cells, PAK4 was involved in the stabilization of PD-L1 from ubiquitin-mediated proteasomal degradation and the in vivo infiltration of immune cells such as regulatory T cells and PD1-, CD4-, and CD8-positive cells in mice tumors. In conclusion, this study suggests that PAK4 is involved in the progression of osteosarcoma by promoting proliferation, invasion, and resistance to doxorubicin and stabilized PD-L1 from proteasomal degradation.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
|
CD8 positive • PAK4 overexpression
|
doxorubicin hydrochloride
2ms
Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas. (PubMed, Cancers (Basel))
These diseases may have different clinical manifestations and distinctive treatment algorithms. Due to the rare nature of these diseases, it is imperative to integrate clinical, histologic, and immunohistochemical findings to determine an accurate diagnosis and an appropriate treatment plan.
Review • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
CD8 positive
2ms
Clinicopathologic and prognostic characteristics of tumor budding-like in giant cell tumor of bone. (PubMed, Cancer)
The current data support the assessment of TBL structures as a reliable prognostic tool in GCTB, potentially aiding in the development of personalized treatment strategies for patients.
Journal
|
PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
CD20 positive • CD8 positive • CD4 positive
|
Prolia (denosumab)
2ms
High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma. (PubMed, Cancer Immunol Immunother)
Resected OAC are variably infiltrated by PD-1 and CD39 DP TILs, an abundance of which among lymphocytes is associated with improved survival. This DP population has an increased, but still modest, frequency of TIM3 and LAG3 positivity compared to DN, and is in keeping with a functionally competent TRM phenotype.
Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • ITGAE (Integrin Subunit Alpha E) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
CD8 positive
6ms
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib (clinicaltrials.gov)
P2; Trial completion date: Apr 2025 --> Apr 2028 | Trial primary completion date: Apr 2024 --> Apr 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8)
|
HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive
|
HercepTest
|
Verzenio (abemaciclib) • letrozole
6ms
Study of metal organic framework with siRNA for overcoming matrix barrierin breast cancer (PubMed, Zhonghua Zhong Liu Za Zhi)
No significant abnormalities were observed in the main organs of mice. Targeting the integrinαv on the surface of cancer cells could destroy extracellular matrix, improve drug delivery, and increase immune infiltration.
Journal
|
CD8 (cluster of differentiation 8) • TGFB1 (Transforming Growth Factor Beta 1) • ITGAV (Integrin Subunit Alpha V)
|
CD8 expression • CD8 positive
7ms
Radiological Features for Predicting the Status of CD8-Positive Lymphocytes in HER2 Positive Breast Cancer. (PubMed, Balkan Med J)
US features (shape, orientation, and posterior echo) and ADC value may be a valuable tool for estimating CD8+-TIL levels in HER2-positive BC. The nomogram may help clinicians in making decisions.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8)
|
HER-2 positive • CD8 positive
7ms
Assessment of cancer cell-expressed HLA class I molecules and their immunopathological implications. (PubMed, HLA)
Correlations between prognosis and the integrity of HLA class I molecules expressed by cancer cells have been consistently found across different types of cancer. This paper provides an overview of the regulatory mechanisms of HLA class I molecules and their role in cancer immunotherapy, with a particular emphasis on the significance of utilizing pathological tissues to evaluate HLA class I molecules expressed in cancer cells.
Review • Journal
|
CD8 (cluster of differentiation 8)
|
CD8 positive
7ms
Primary Cutaneous Acral CD8-Positive Lymphoproliferative Disorder: A Case Report With Nonacral Presentation. (PubMed, Int J Surg Pathol)
To our knowledge, < 20 patients of primary cutaneous acral CD8-positive lymphoproliferative disorder with a nonacral presentation have been described in English literature. Although rare, its identification is essential to differentiate it from other T-cell lymphoma that express CD8 and cytotoxic markers, and whose clinical courses are very aggressive.
Journal
|
CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule)
|
CD8 positive
7ms
USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF. (PubMed, Clin Transl Med)
USP7-mediated reprograming of the TME is not linked to its previously characterized role in modulating MDM2 but does require p53 and UHRF1 in addition to the well-characterized VEGF transcription factor, HIF-1α. This represents a function of USP7 that is unique to fibroblasts, and which is not observed in cancer cells or other components of the TME. Given the potential for USP7 inhibitors to transform "immune desert" tumors into "immune responsive" tumors, this paves the way for a novel therapeutic strategy combining USP7 inhibitors with immune checkpoint inhibitors (ICIs).
Journal • Checkpoint inhibition
|
CD8 (cluster of differentiation 8) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1) • USP7 (Ubiquitin Specific Peptidase 7)
|
CD8 positive
7ms
Clinical, Epidemiological, Morphological, and Immunohistochemical Aspects of Nasopharyngeal Carcinoma-4-Year Retrospective Study in the Western Part of Romania. (PubMed, Diagnostics (Basel))
The T cells were CD4- and CD8-positive, predominantly intratumoral, and the CD4:CD8 ratio was 1:1 for 75% of the undifferentiated subtype and 89% for differentiated non-keratinized squamous cell carcinoma. All subtypes of nasopharyngeal carcinoma presented with an inflammatory infiltrate with numerous plasma cells, eosinophils, and dendritic cells, presenting as antigen CD1a- and CD68-positive, as well as in CD117-positive mast cells.
Retrospective data • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • TP63 (Tumor protein 63)
|
CD20 positive • CD8 positive • CD68 positive
7ms
A Study of Ruxolitinib and Duvelisib in People With Lymphoma (clinicaltrials.gov)
P1, N=49, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed
|
CD8 (cluster of differentiation 8)
|
CD8 positive
|
Jakafi (ruxolitinib) • Copiktra (duvelisib)
8ms
Extranodal natural killer/T-cell lymphoma coexisting with peripheral T-cell lymphoma, not otherwise specified. (PubMed, J Clin Exp Hematop)
However, ascites did not improve when treated with micafungin for Candida peritonitis. PTCL-NOS, chemotherapy, sepsis, and prednisone might have led to immunodeficiency and reactivation of EBV, which might be one of the pathophysiologies for developing ENKTL. Our case indicates that measuring EBV-DNA in the blood is a simple and prompt examination to detect complications of EBV-associated lymphoma.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule)
|
CD8 positive • CD4 positive
8ms
CD8-positive T Cell Infiltration With Human Leukocyte Antigen Class 1 Expression Predicts Patients With Stage IV Colorectal Cancer Survival. (PubMed, Anticancer Res)
The combination of CD8+ T cell infiltration and HLA1 expression is crucial for cancer immune microenvironment evaluation in CRCs.
Journal • Metastases
|
CD8 (cluster of differentiation 8)
|
CD8 expression • CD8 positive • CD8-H
8ms
Emerging measurements for tumor-infiltrating lymphocytes in breast cancer. (PubMed, Jpn J Clin Oncol)
We also discuss higher resolution technologies that enable the analysis of tumor-infiltrating lymphocytes heterogeneity such as single-cell analysis and spatial transcriptomics. As we approach the era of personalized medicine, it is important for clinicians to understand these technologies.
Journal • Tumor-infiltrating lymphocyte • IO biomarker
|
CD8 (cluster of differentiation 8)
|
CD8 positive
8ms
Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy. (PubMed, Mol Ther Methods Clin Dev)
ΔNPM1 TCR CD8 T cells manufactured with the optimized process showed specific killing of AML in vitro and in vivo. The process has been implemented in an upcoming phase 1/2 clinical trial for the treatment of NPM1-mutated AML.
Journal
|
NPM1 (Nucleophosmin 1) • CD8 (cluster of differentiation 8)
|
NPM1 mutation • CD8 positive
8ms
Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors. (PubMed, J Cancer Res Clin Oncol)
Our study highlights the predictive value of IHC-classified subtypes and CD8-positive cell infiltration in estimating outcomes for patients with ED-SCLC treated with chemoimmunotherapy as a first-line therapy. These findings have practical implications for daily clinical assessments and treatment decisions.
Journal • Checkpoint inhibition • IO biomarker • Biopsy
|
CD8 (cluster of differentiation 8) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1)
|
CD8 positive • CD8-H
8ms
An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy. (PubMed, Biochim Biophys Acta Mol Basis Dis)
In addition, oAdQ2 treatment enhanced T cell and IFNγ-positive CD8 T lymphocyte infiltration in a human PBMC reconstituted-SCID mouse xenograft model. This study provides evidence that reengineering of bioactive cytokines with tissue or cell specific properties may potentiate their therapeutic potential of cytokines with multiple receptors.
Journal • Oncolytic virus • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFRSF1A (TNF Receptor Superfamily Member 1A)
|
CD8 positive
8ms
A landscape of patient-derived cancer-associated fibroblast signals in endometrial cancers. (PubMed, Am J Cancer Res)
We demonstrate that endometrial CAFs can be cultured in an enzymatic-digestion-independent manner, and their signaling landscape can be mapped toward understanding CAF-TME dialogue. Our data will help unearth the functional relevance of endometrial CAFs in the context of clinical outcomes and designing CAF-inclusive therapy in the future.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule) • VIM (Vimentin) • FAP (Fibroblast activation protein, alpha) • PVR (PVR Cell Adhesion Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • THY1 (Thy-1 membrane glycoprotein) • MMP1 (Matrix metallopeptidase 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • S100A4 (S100 calcium binding protein A4)
|
CD8 positive • CD44 expression • CXCL12 expression • VIM expression • EPCAM expression
8ms
HOXC9 characterizes a suppressive tumor immune microenvironment and integration with multiple immune biomarkers predicts response to PD-1 blockade plus chemotherapy in lung adenocarcinoma. (PubMed, Aging (Albany NY))
The expression of HOXC9 may serve as a biomarker to amplifying predictive efficacy for ICIs plus chemotherapy, which is also a viable oncogene and therapeutic target for immunotherapy in LUAD.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3)
|
CD8 positive
9ms
Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding. (PubMed, Cancer)
A novel strategy for predicting the prognosis of patients with TNBC was established through integrated AI-based analysis and a machine-learning workflow. The TLS/TB index was identified as an independent prognostic factor for TNBC. This nomogram-based TLS-TB profile would help improve the accuracy of predicting the prognosis of patients who have TNBC.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8)
|
CD20 positive • CD8 positive
9ms
Granzyme F: Exhaustion Marker and Modulator of Chimeric Antigen Receptor T Cell-Mediated Cytotoxicity. (PubMed, J Immunol)
To determine the function of granzyme F and to improve the cytotoxic response to leukemia, we constructed chimeric Ag receptor T cells to overexpress a single granzyme, granzyme F or the better-characterized granzyme A or B. Using these doubly recombinant T cells, we demonstrated that granzyme F expression improved T cell-mediated cytotoxicity against target leukemia cells and induced a form of cell death other than chimeric Ag receptor T cells expressing only endogenous granzymes or exogenous granzyme A or B. However, increasing expression of granzyme F also had a detrimental impact on the viability of the host T cells, decreasing their persistence in circulation in vivo. These results suggest a unique role for granzyme F as a marker of terminally differentiated CD8 T cells with increased cytotoxicity, but also increased self-directed cytotoxicity, suggesting a potential mechanism for the end of the terminal exhaustion pathway.
Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • GZMA (Granzyme A)
|
CD8 positive
9ms
The role of PD-L1 and TILsCD8+ in oral cavity and pharyngeal cancers treated with definitive radiation (ICHNO 2024)
Material/Methods It was a retrospective single-center analysis involving OC and PX patients who underwent radical RT (66Gy prescribed to the primary tumor, given in 30 fx/6 weeks) with or without concurrent chemotherapy (Cisplatin 100 mg/m2 i.v. every three weeks or 40 mg/m2 i.v weekly)...In univariate analysis we did not find any predictive factors for RT response. The main limitation of our study was very small group sizes.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • PD-L1 negative • CD8 positive • CD8 negative
|
VENTANA PD-L1 (SP263) Assay • Ventana CONFIRM anti-CD8 (SP57) Rabbit Monoclonal Primary Antibody
|
cisplatin
9ms
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer. (PubMed, J Immunother Cancer)
The spatial analysis of the TIME using machine learning predicted the immunotherapy efficacy in patients with SCLC, thus supporting its role as an immunotherapy biomarker.
Journal • PD(L)-1 Biomarker • IO biomarker • Machine learning
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • FOXP3 (Forkhead Box P3)
|
CD8 positive
9ms
High ANO1 expression is a prognostic factor and correlated with an immunosuppressive tumor microenvironment in pancreatic cancer. (PubMed, Front Immunol)
ANO1 is a prognostic factor in patients with PC after radical resection. ANO1 may induce an immunosuppressive tumor microenvironment in PC in a paracrine manner, suggesting that ANO1 may be a novel therapeutic target.
Journal
|
CD8 (cluster of differentiation 8) • FAP (Fibroblast activation protein, alpha) • FOXP3 (Forkhead Box P3) • ANO1 (Anoctamin 1)
|
CD8 positive • FAP expression
9ms
GITRL impairs hepatocyte repopulation by liver progenitor cells to aggravate inflammation and fibrosis by GITR+CD8+ T lymphocytes in CDE Mice. (PubMed, Cell Death Dis)
Mechanistically, GITRL stimulated cell proliferation but suppressed the differentiation of liver progenitor organoids into hepatocytes, and CD8+ T cells further reduced their hepatocyte differentiation by downregulating the Wnt/β-catenin pathway. Therefore, GITRL expressed by liver progenitor cells impairs hepatocyte differentiation, thus hindering progenitor cell-mediated liver regeneration.
Preclinical • Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • SOX9 (SRY-Box Transcription Factor 9)
|
CD8 positive
9ms
Clinical effect of laparoscopic radical resection of colorectal cancer based on propensity score matching. (PubMed, World J Gastrointest Surg)
Laparoscopic radical resection of CRC has significant benefits, such as reducing postoperative pain and postoperative inflammatory response, avoiding excessive immune inhibition, and contributing to postoperative recovery.
Journal
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • CRP (C-reactive protein)
|
CD8 positive • CD4 positive
9ms
Subcutaneous panniculitic-like T-cell lymphoma localized to a site of peginterferon alfa-2a administration. (PubMed, Leuk Lymphoma)
Peginterferon alfa-2a is known to significantly elevate serum MXA, which may induce high levels of MXA expression at the injection site, creating a microenvironment for the development of lupus profundus, which may eventuate into SPTCL. In summation, a potential risk of peginterferon alfa-2a injections is the development of SPTCL potentially arising in a background of an exogenous interferon triggered lymphocytic panniculitis.
Journal
|
CD8 (cluster of differentiation 8) • CD5 (CD5 Molecule)
|
CD8 positive
10ms
Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
FH and 2SC are immunohistochemical markers used in the diagnosis of FH-deficient renal cell carcinoma, and GATA3 positivity is supportive of the diagnosis. The tumor infiltration of high-grade FH-deficient renal cell carcinoma shows an increase in CD4 and CD8 positive T-lymphocytes, and high expression of PD-L1; thus, anti-PD-L1 immunotherapy can be used as a treatment option.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FH (Fumarate Hydratase) • GATA3 (GATA binding protein 3)
|
PD-L1 overexpression • CD8 positive